RSE ARCHIVE MACALLAN3 by RSE ARCHIVE LLC. Stock (OTC: RMCLS)

Latest news for RSE ARCHIVE MACALLAN3 by RSE ARCHIVE LLC. (OTC:RMCLS) Stock

RSE ARCHIVE MACALLAN3 by RSE ARCHIVE LLC.

Keybanc analyst Alex Markgraff maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Overweight and raises the price target from $140 to $142.

News

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Trade Desk, Raises Price Target to $142

WIIM

MBLY

Mobileye Global shares are trading higher after B of A Securities upgraded the stock from Underperform to Neutral and raised its price target from $12 to $19.

Biotech

General

BCRX

Biocryst Pharmaceuticals Announces The Company Will Present Five Abstracts Featuring New Clinical And Real-World Outcomes With Oral, Once-Daily Orladeyo For The Prophylactic Treatment Of Hereditary Angioedema At The 2025 American Academy Of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress.

Barclays analyst Andrew Lazar maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Equal-Weight and lowers the price target from $170 to $160.

Barclays Maintains Equal-Weight on Hershey, Lowers Price Target to $160

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic's Specialty Diagnostic Suite
GeneDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic's specialty diagnostics suite, offering advance genetic sequencing within health systems electronic health records (EHR) to receive orders and send results. GeneDx is expanding access to its industry leading diagnostic tests for health systems to deliver fast and accurate genetic diagnoses to patients and accelerate the path to treatment, with UNC Health becoming the first health system to integrate with GeneDx through Aura. Effective today, additional health systems can connect via Aura to order GeneDx's tests including exome sequencing (ES), whole genome sequencing (WGS) and rapid whole genome sequencing (rWGS).

GeneDx Announces Its Launch On Aura, Epic's Specialty Diagnostics Suite, Offering Advance Genetic Sequencing Within Health Systems Electronic Health Records To Receive Orders And Send Results

Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock is trading lower on Monday.
On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43574512/pliant-therapeutics-provides-update-on-beacon-ipf-a-phase-2b3-trial-in-patients-with-idiopathic-pu" rel="noreferrer noopener">idiopathic pulmonary fibrosis (IPF)</a>, a chronic lung disease that causes scarring and stiffening of the lung tissue.&nbsp;
Patients currently enrolled in BEACON-IPF will remain in the trial.
The move follows a prespecified data review and recommendations by the trial&#8217;s independent Data Safety Monitoring Board.
Enrollment and dosing have been paused while data are reviewed to understand the DSMB&#8217;s rationale for their recommendation. The study will be blinded to preserve trial integrity.
In May 2024, On Tuesday,&nbsp;Pliant Therapeutics announced topline data from a Phase 2a PET Imaging trial of&nbsp;bexotegrast&nbsp;(PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38819267/pliant-therapeutics-drug-trial-shows-promise-in-reversing-lung-fibrosis-in-patients" rel="noreferrer noopener">deposition in the lung</a>.
Bexotegrast-treated patients showed reduced total lung collagen post-treatment as measured by positron emission tomography (PET) imaging, compared to increased total lung collagen in the placebo group, suggesting potential reversal of fibrosis.&nbsp;
Last February, Pliant Therapeutics released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36937322/why-is-liver-disease-focused-pliant-therapeutics-stock-trading-lower-today" rel="noreferrer noopener">moderate to severe liver fibrosis</a>.&nbsp;
The 320 mg group met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated over a 12-week treatment period, and its plasma concentrations increased with dose.&nbsp;
There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.
Price Action: PLRX stock is down 64.10% at $2.80 during the premarket session at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43570574/netflix-eyes-formula-one-us-broadcast-rights-starting-in-2026-report" target="_blank" rel="noreferrer noopener">Netflix Eyes Formula One US Broadcast Rights Starting In 2026</a></li>
</ul>

Health Care

Movers

Trading Ideas

PLRX

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Keybanc analyst Alex Markgraff maintains i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) with a Overweight and raises the price target from $27 to $32.

IIIV

Keybanc Maintains Overweight on i3 Verticals, Raises Price Target to $32

Barclays analyst Matt Miksic maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $418 to $443.

Barclays Maintains Overweight on Stryker, Raises Price Target to $443

Keybanc analyst Justin Patterson maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and raises the price target from $55 to $65.

GLBE

Keybanc Maintains Overweight on Global E Online, Raises Price Target to $65

Barclays analyst Adrienne Yih maintains Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Overweight and lowers the price target from $80 to $77.

Barclays Maintains Overweight on Skechers USA, Lowers Price Target to $77

ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) released its Q4 earnings on Monday, February 10, 2025 at 07:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
ON Semiconductor missed estimated earnings by -2.0%, reporting an EPS of $0.95 versus an estimate of $0.97.
Revenue was down $295.00 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 3.0% increase share price change the next day.
Here's a look at ON Semiconductor's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.97</td>
<td>0.92</td>
<td>1.04</td>
<td>1.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>0.96</td>
<td>1.08</td>
<td>1.25</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.75B</td>
<td>1.73B</td>
<td>1.85B</td>
<td>2.00B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.76B</td>
<td>1.74B</td>
<td>1.86B</td>
<td>2.02B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
ON Semiconductor management provided guidance for Q1 2025, expecting earnings between $0.45 and $0.55 per share.
To track all earnings releases for ON Semiconductor <a href="https://www.benzinga.com/quote/ON/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Breakdown: ON Semiconductor Q4

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Perform and raises the price target from $176 to $179.

Keefe, Bruyette & Woods Maintains Market Perform on Hanover Insurance Gr, Raises Price Target to $179

Keybanc analyst Matthew Gillmor maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Overweight and raises the price target from $117 to $120.

Keybanc Maintains Overweight on Encompass Health, Raises Price Target to $120

Barclays analyst Matthew Bouley maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Equal-Weight and lowers the price target from $130 to $125.

Barclays Maintains Equal-Weight on Mohawk Industries, Lowers Price Target to $125

Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/quote/AMZN/earnings">latest earnings call</a> sent investors into a brief panic, with shares slipping 4% post-report. But was it really thesis-changing? 
JPMorgan's Doug Anmuth doesn't think so. The big talking point? 
Amazon Web Services&#8217; (AWS) growth trajectory and a single word from Amazon's scripted remarks: &#8220;lumpy.&#8221;
<h2 class="wp-block-heading">AWS &amp; AI: The Perfect Growth Catalyst?</h2>
Lumpy isn't usually a word that rattles Wall Street, but the Street heard &#8220;volatile&#8221; instead of &#8220;long-term upside.&#8221; AWS growth is expected to slow in early 2025 before accelerating in the second half, with CEO Andy Jassy assuring investors that supply constraints should ease. But that's contingent on Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips, Trainium2, and a host of tech bottlenecks playing along. Anmuth remains optimistic, standing by an 18% AWS growth forecast for 1H25, ramping past 20% in 2H25 and beyond.
Read Also: <a href="https://www.benzinga.com/25/02/43570975/amazon-to-rally-over-20-here-are-10-top-analyst-forecasts-for-friday">Amazon To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Friday</a>
Meanwhile, Amazon's 2025 capex outlook of $105 billion—well above Street expectations—has some investors worried about free cash flow. But Anmuth argues that AI investments will pay off, likening Amazon's infrastructure push to the competitive advantages enjoyed by Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google.
If Jevons Paradox holds true, lower inference costs could actually boost AWS revenue, as customers deploy more AI-driven applications.
Beyond cloud, Amazon's international business faces macroeconomic headwinds, particularly in Germany where growth has decelerated. FX pressures and last year's leap day also complicate Q1 revenue comps. Still, Amazon's logistics efficiency continues to improve, with same-day delivery expansion and robotics-driven cost reductions providing a silver lining.
<h2 class="wp-block-heading">Investor Takeaway: Is Amazon Set For A Big Move?</h2>
So what's the bottom line? Anmuth sees Amazon as a multi-year winner in both e-commerce and cloud, even if the road ahead has some bumps. His $270 price target reflects confidence in Amazon's AI monetization and operating margin expansion. For long-term investors, the message is clear: ignore the lumps, follow the growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43577796/cathie-woods-ark-invest-bets-big-on-amazon-roblox-and-illumina-while-trimming-palantir-stake-after-alex-karp-led-company-touched-an-all-time-high-on-thursday">Cathie Wood&#8217;s Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake</a></li>
</ul>

Analyst Color

Long Ideas

Tech

AMZN

GOOG

GOOGL

NVDA

Amazon's AI Bet Is Big, But Will Investors Stick Around For The 'Lumps'?

Barclays analyst Michael Leithead maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Equal-Weight and raises the price target from $54 to $57.

MEOH

Barclays Maintains Equal-Weight on Methanex, Raises Price Target to $57

Keefe, Bruyette &amp; Woods analyst Michael Brown maintains Perella Weinberg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>) with a Outperform and raises the price target from $27 to $29.

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

Keefe, Bruyette & Woods Maintains Outperform on Perella Weinberg, Raises Price Target to $29

Elliott Management, a U.S.-based activist hedge fund managing approximately $70 billion in assets, has reportedly acquired a stake in oil giant BP plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>).
Elliott is advocating for substantial changes at the British oil company to boost its performance, according to a <a target="_blank" href="https://www.wsj.com/business/energy-oil/elliott-takes-stake-in-struggling-oil-giant-bp-815efbd7" rel="noreferrer noopener">report </a>from the Wall Street Journal.
The hedge fund&#8217;s engagement with BP suggests rising discontent with the company&#8217;s current path, particularly as BP&#8217;s market value trails behind competitors such as Shell and Exxon Mobil, per the report. BP&#8217;s leadership has been dealing with elevated debt levels and a declining stock price.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, BP stock lost over 11% in the last year.
Recently, BP announced 4,700 jobs cut in January, representing 5% of its workforce, and removing over <a target="_blank" href="https://www.benzinga.com/news/global/25/01/43038940/bp-slashes-workforce-by-5-to-reach-2-billion-in-savings-goal" rel="noreferrer noopener">3,000 contractor positions.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps" rel="noreferrer noopener">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection</a>
The energy giant is planning to streamline its operations and lower expenses as part of a broader effort to save $2 billion by the end of 2026.
Also, BP&#8217;s choice to lower its oil and gas production reduction goals for 2030 has sparked debate, although some <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36829332/battleground-for-oil-majors-bp-activist-investor-calls-for-cut-in-green-energy-pled" rel="noreferrer noopener">investors backed the move. </a>In 2020, the company aimed to cut its oil and gas output by 40% by 2030, a target that was ultimately <a target="_blank" href="https://www.bp.com/en/global/corporate/sustainability/getting-to-net-zero/five-aims-to-get-bp-to-net-zero.html" rel="noreferrer noopener">scrapped in October 2024</a>.
For the fourth quarter, BP anticipates a decline in upstream production compared to the previous quarter, with decreases in both oil and gas &amp; low-carbon energy output.
Within the oil production &amp; operations division, the company expects price lags, particularly in the Gulf of Mexico and UAE, to result in an unfavorable impact of $0.2 billion to $0.4 billion on realizations.
BP has been facing history of challenges over the last 15 years, including the Deepwater Horizon catastrophe and the abrupt firing of <a target="_blank" href="https://www.benzinga.com/markets/equities/23/09/34526407/oil-giant-bps-ceo-resigns-amid-investigation-on-personal-conduct" rel="noreferrer noopener">former CEO Bernard Looney</a> due to personal misconduct, reported <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-02-09/bp-faces-pivotal-moment-as-activist-investor-elliott-enters-fray?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>.
Price Action: BP shares are trading higher by 6.76% at $34.45 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43565687/wearable-devices-unveils-advanced-ai-powered-gesture-control-details" target="_blank" rel="noreferrer noopener">Wearable Devices Unveils Advanced AI-Powered Gesture Control</a></li>
</ul>
Photo: Jon Lyall via Shutterstock.

Equities

Large Cap

Media

What's Going On With Oil Giant BP Stock Today?

TD Securities analyst Agnes Lim reiterates McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Hold and maintains $300 price target.

Reiteration

TD Securities Reiterates Hold on McDonald's, Maintains $300 Price Target

Barclays analyst David Strauss maintains Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) with a Equal-Weight and lowers the price target from $220 to $200.

Comments

RSE ARCHIVE MACALLAN3 by RSE ARCHIVE LLC.

News

Latest news for RSE ARCHIVE MACALLAN3 by RSE ARCHIVE LLC. (OTC:RMCLS) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga